Assessment of the anti-norovirus activity in cell culture using the mouse norovirus: Identification of active compounds

Jana Van Dycke, Jasper Rymenants, Johan Neyts and Joana Rocha-Pereira

Abstract
Human norovirus is the main cause of viral gastroenteritis, resulting annually in ~700 million infections and 200,000 deaths, of whom most are children <5 years. Mouse norovirus-infected macrophages are the most widely used in vitro system to screen and characterize the antiviral effect of norovirus-targeting small molecules. We have previously established antiviral assays using this system, identified novel inhibitors and performed additional studies in order to have a first insight into their mechanism of action. As potent and safe anti-norovirus small molecules are urgently needed, we here describe the detailed protocol for a set of assays that will allow the identification of novel norovirus inhibitors.

Keywords
Infection, compounds, inhibitors, virus

Date received: 19 February 2021; accepted: 2 June 2021

Introduction
Human noroviruses (HuNoVs) infections are mostly acute and self-limiting, although chronic norovirus infections occur in patients with an immunodeficient state.1–3 Despite the yearly global impact of ~700 million HuNoV infections, 219,000 deaths and 60 billion dollars in societal costs there is no specific antiviral therapies to treat (chronic) norovirus gastroenteritis. To assess the anti-norovirus effect of small molecules, we describe in detail the use of mouse norovirus (MNV, CW1)-infected mouse macrophages (RAW264.7 cells) as cell-based antiviral assays for the identification and characterization of anti-norovirus activity and mechanism of action in vitro.4,5 As there are still no routine cell culture systems to study HuNoV replication and inhibition thereof in high-throughput manner, this model system is most easily accessible and cost-efficient solution for large scale screenings on antinorovirus activity.

We here describe the assessment of the antiviral activity of the selected compounds by two different methods which are complementary. Besides that, the toxicity of the compounds needs to be assessed to determine the therapeutic window. Compounds to be tested could include all those with previously reported antiviral activity against other +ssRNA viruses, libraries of compounds available from commercial suppliers (e.g. FDA-approved drugs) or from academic partners and institutions. The concentrations to test initially are normally in the μM to mM range.

Another, more sensitive, assay such as a plaque reduction assay could also be used to determine antiviral activity.6 However, this technique is more laborious and very time-consuming, with the extra difficulty of using semi-adherent macrophages in an assay in which strong adherence of cells is required. Moreover, using the CPE-based assay as described...
here, weaker antiviral compounds could be selected which give room for optimization and production of potentially more potent analogues.

**Expertise needed to implement the protocol**

The scientist needs to be trained to work with cell culture and pathogens at BSL-2 level.

**Materials and reagents**

1. Appropriate personal protection to work in a biosafety level 2 (BSL-2) laboratory (gloves, lab coat, shoe covers, safety glasses)
2. Disinfectant: bleach (5,000 ppm) or Virkon S.
3. Culture flasks (150 cm², TPP, catalog number: 90856)
4. Cell scrapers (Corning, Falcon®, catalog number: 353086)
5. Cryotubes (Thermo Fisher Scientific, Thermo Scientific, catalog number: 377224)
6. Pipet filter tips (10 µL, 100 µL, 1,000 µL)
7. Disposable serological pipets (5 mL, 10 mL, 25 mL)
8. Disposable aspirator pipets (Falcon, catalog number: 357558)
9. Murine macrophage cells (RAW 264.7, ATCC, catalog number: TIB-71)
10. Murine norovirus (MNV-CW1, ATCC, catalog number: VR-1937)
11. Dulbecco’s phosphate buffered saline (PBS) (Thermo Fisher Scientific, catalog number: 14190094)
12. Dulbecco’s modified eagle’s medium (DMEM) (Thermo Fisher Scientific, GibcoTM, catalog number: 41965039)
13. Fetal calf serum (FCS) (Thermo Fisher Scientific, GibcoTM, catalog number: 10270106)
14. Sodium bicarbonate (Thermo Fisher Scientific, GibcoTM, catalog number: 25080060)
15. L-Glutamine (Thermo Fisher Scientific, GibcoTM, catalog number: 25030024)
16. HEPES (Thermo Fisher Scientific, GibcoTM, catalog number: 15630056)
17. Penicillin/streptomycin (P/S) (Thermo Fisher Scientific, GibcoTM, catalog number: 15140148)
18. Sodium pyruvate (Thermo Fisher Scientific, GibcoTM, catalog number: 11360039)
19. Minimal Essential Medium (MEM) without phenol red (Thermo Fisher Scientific, GibcoTM, catalog number: 51200046)
20. Eppendorf safe-lock tubes, 1.5 mL (Eppendorf, catalog number: 0030120086)
21. 2’-C-methylcytidine (2CMC, Carbosynth, catalog number: NM07918)
22. Falcon tubes 50 mL (Greiner Bio-one, catalog number: 227261)
23. CellTiter 96 AQueous MTS Reagent Powder (MTS, Promega, catalog number: G1111)
24. 96-well plate (Falcon, catalog number: 353072)
25. Phenazine methosulfate (PMS, Sigma, catalog number: P9625)
26. Filter 0.22 µm (Thermo Scientific Nalgene catalog number: 161–0020)
27. Trypan Blue Stain, 0.4% (Logos Biosystems; Catalog number: T13001)
28. MNV forward primer: 5’-CAC GCC ACC GAT CTG TTC TG-3’ (Integrated DNA Technologies)⁷
29. MNV reverse primer: 5’-GCG CTG CGC CAT CAC TC-3’ (Integrated DNA Technologies)⁷
30. MNV RT-qPCR standard: 5’- tagaatgtgtggcc aecgccacgtgtctgcg ctgggtgcgctttggaacaatgga tgcggacccgacaagctcagttttttgtgaatgaggagt agtgatgggcaaegeccaatgct -3’ (Integrated DNA Technologies)⁶
31. MNV probe: 6-FAM–MGB 5’-CGC TTT GGA ACA ATG-3’ (Thermo Fisher Scientific)⁶
32. RT-qPCR kit (iTaq Universal Probes One-Step Kit Catalog number: 1725141)

**Equipment**

1. Biosafety hood in a BSL-2 laboratory
2. Incubator (37°C, 5% CO₂, humidified)
3. Pipet set (P10, P100, P1000)
4. Pipetboy (Integra Biosciences, catalog number: 155016)
5. Multipette® M4 (Eppendorf, catalog number: 4982000012)
6. Multichannel pipette (Eppendorf, catalog number: 3122000035)
7. –80°C freezer
8. PCR Workstation
9. Vortex
10. Centrifuge with a rotor suitable for 1.5 mL tubes
11. Centrifuge with a rotor suitable for 50 mL tubes
12. Inverted light microscope
13. Cell counter (Logos Biosystems Luna-II automated Cell counter, catalog number L400002)
14. Aspirator (Integra BioSciences Vacusafe catalog number: 158320)
15. Plate reader (SPARK® Multimode Microplate Reader)
16. Stirring plate
17. pH meter
Procedures

Note: Culture cells under a biosafety hood.
Note: Infect cells under a biosafety hood in a BSL-2 laboratory.

Cultivation of RAW 264.7 cells

1. Thaw RAW264.7 cells and seed these in 10% culture media (see recipes).
2. Grow the RAW264.7 cells in a CO2 incubator at 5% CO2 and 37°C.
3. Maintain the RAW264.7 cells by splitting of the cells once a week at a 1:10 ratio in a T-150 flask.

Expansion and quantification of Murine Norovirus. CW1 virus stock

1. When the RAW264.7 cells are ~90% confluent infect the monolayer with MNV.CW1. When full cytopathic effect (CPE) is observed (~2–3 days post infection, see Figure 1) perform two freeze-thaw cycles (~80°C vs. 37°C), collect the supernatants containing the virus after centrifugation (10 min, 1 500 x g) and store aliquots (500-1 000 µL) in cryotubes at ~80°C.
2. Determine the viral titer by endpoint titration as previously described in Reed et al. (1938).

Assessment of anti-norovirus activity

1. Add 100 µL of 2% culture media in all wells of a 96-well plate (see Figure 2).
2. Add 25 µL of 2% culture media in the first column.
3. Add the appropriate volume of compound to 1B-1G. It is recommended to include a reference compound such as 2CMC5 at least once in a set of test plates. In each plate, rows A and H, columns 1 and 12 are not used for the assay, but simply to buffer the test wells, avoiding evaporation effects.
4. Mix the compound and medium with a multichannel pipette by pipetting up and down at least three times.

Figure 1. Macroscopic view of virus induced CPE. Left: uninfected RAW264.7 cells after 3 days, Right: MNV-infected RAW264.7 cells after 3 days.

Figure 2. Layout of the dilution series of selected compounds on RAW 264.7 cells (1 x 10⁶ cells/well). Antiviral assay (top) and cellular toxicity assay (bottom) in a 96-well plate. Created with BioRender.com.
5. Take 100 μL of the compound dilution and transfer into the next column (e.g. 2B-2G).
6. Repeat steps 3–4 until reaching column 9 of the 96 well plate. Changing tips between rows is not required but might yield better results with some compounds (e.g. more viscous compounds).
7. Mix the compound and medium in column 9 and discard 100 μL.
8. Scrape the RAW 264.7 cells from a tissue culture flask using 5 mL of fresh assay media, homogenize the suspension by pipetting vigorously up and down and then determine the density of the cell suspension (cells/mL).
9. Prepare a 10,000 cells/50 μL in 2% culture media, by diluting appropriately the cell suspension.
10. Prepare a virus dilution (which is 4 times more concentrated then the desired final concentration, MOI of 0.1) in 2% culture media.
11. Add 50 μL of virus suspension to each well of rows 2–10.
12. Add 50 μL of the cell suspension to the inner 60 wells of the 96-well plate (rows 2–11, columns B-G).
13. Incubate the 96-well plate for 72 h in a CO2 incubator at 5% CO2 and 37°C.
14. Assess the antiviral effect of the compounds via an MTS assay and virus yield assay.
15. Calculate the EC50 value by logarithmic intrapolation.

Assessment of cellular toxicity

1. Add 100 μL of 2% culture media in all wells of a 96-well plate (see Figure 2).
2. Add 25 μL of 2% culture media in the first column.
3. Add the appropriate volume of compound to 1B-1G. In each plate, rows A and H, columns 1 and 12 are not used for the assay, but simply to buffer the test wells, avoiding evaporation effects.
4. Mix the compound and medium with a multichannel pipette by pipetting up and down at least three times.
5. Take 50 μL of the compound dilution and transfer into the next column. Tip change is an option; proceed here the same way than for the antiviral assay.
6. Repeat steps 5–6 until reaching column 9 of the 96 well plate.
7. Homogenize the compound and medium in row 9 and discard 50 μL.
8. Count the RAW 264.7 cells/mL of cell suspension and prepare a 10,000 cells/100 μL in 2% culture media.
9. Add 100 μL of the cell suspension to the inner 60 wells of the 96-well plate.
Table 1. Troubleshooting advice.

| Problem                                                                 | Possible reason                                      | Solution                                                                                                                                 |
|------------------------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| The OD value is not as expected.                                       | The OD value is too low.                             | Make sure that the correct amount of RAW264.7 cells were seeded and that they grew as expected. Make sure that the right dilution of MTS has been used. Incubate the plate for 30 min longer and repeat the read-out. If after this period the values are still not in range, this data cannot be used and the assay needs to be repeated. Make sure that the correct amount of RAW264.7 cells were seeded. Make sure that the right dilution of MTS is been used. The plate was incubated for an excessive period. This data cannot be used and the assay needs to be repeated. |
| The OD value is too high.                                              |                                                      | Make sure that the correct amount of RAW264.7 cells were seeded. Make sure that the right dilution of MTS is been used. The plate was incubated for an excessive period. This data cannot be used and the assay needs to be repeated. |
| Crystals can be seen in the plate wells under a microscope.            | The compound concentration is too high.             | Analyze under the microscope which concentration is still soluble and use this as a start concentration in your next assay. Alternatively, note down which compound concentrations yield crystals. Interpret data generated in such conditions with caution. Make a fresh DMSO solution of the compound. |
| Large variation in data in between assays.                            | The compound could be rather viscous.               | If the compound sticks to the tip a large variation in data in between assays can be observe. This could be avoided by always changing tips when making this compound dilution series. Make a fresh DMSO solution of the compound. |
|                                                                       | The compound is in solution for too long.           | Make a fresh DMSO solution of the compound.                                                                                                                                                        |
|                                                                       | The compound is no longer stable in solution.       | Make a fresh DMSO solution of the compound.                                                                                                                                                        |

**Virus yield assay**

1. Collect the appropriate volume of supernatant (according to the manufacturer’s protocol) of the treated and untreated infected cells in separate and adequately labelled Eppendorf tubes.
2. Extract the viral RNA using an appropriate kit, according to the manufacturer’s protocol. We standardly use the NucleoSpin RNA Virus Kit (Macherey–Nagel).
3. Store the RNA extracts at −20°C for short time storage and at −80°C for long time storage.
4. Perform an RT-qPCR to quantify the RNA levels. Cycling conditions are: reverse transcription at 50°C for 10 min, initial denaturation at 95°C for 3 min, followed by 40 cycles of amplification (95°C for 15 s, 60°C for 30 s). Use 900 nM of primers and 200 nM of probe.
5. Calculate the % of virus yield reduction is calculated as [(number of RNA copies VC)/(number of RNA copies treated cells)]x100. The 50% effective concentration (EC50) is defined as the compound concentration that reduced 50% of the viral RNA in the supernatant.
Expected results
Upon determination of the antiviral effect of a compound, here we give an example of the results to be expected for an active compound. We present a dose-response generated by using the reference compound 2CMC which activity we have described earlier. The antiviral effect has been assessed as described in this protocol; the data was plotted as % of control as shown in Figure 3 using software such as Graphpad Prism. Compounds with EC50 values in the low μM range or lower are considered as having a good antiviral activity. Additionally, the CC50 values should be significantly higher to obtain a good therapeutic window.

Conclusion
This easy and high-throughput assay allows for a good assessment of a high number of compounds for their potential antiviral activity against MNV. Antiviral compounds with a good in vitro anti-mouse norovirus activity can be further assessed for activity in other systems. A potent compound has a good chance of having extended activity against human norovirus, but this, of course, depends on how conserved their molecular target is. Other in vitro systems to consider include the human norovirus GI.1 replicon assay and human intestinal organoids infected with some human norovirus GII genotypes. In vivo systems available include MNV-infected mice, HuNoV GI.4 infected mice (low replication yield) and human norovirus GI and GII infected zebrafish larvae. The antiviral activity can be further studied by some early mechanistical studies, these are described in a follow-up protocol.

Recipes

Culture media for RAW264.7 cells

MTS preparation
! MTS is a light-sensitive reagent, all recipients should be wrapped in aluminum foil and all handlings should be carried out in an as dark as possible environment. ! Freeze the MTS solution in aliquots of 2 mL
- 2 g of MTS
- Dissolve in 1 L sterile PBS
- Stir for 15 min
- Add 46 mg PMS
- Measure pH and adjust to a range of 6–6.5
- Filter the suspension (0.22 μm)
- Freeze at −20°C in aliquots of 2–3 mL

Trouble shooting
See Table 1.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs
Jana Van Dycke https://orcid.org/0000-0003-1632-3499
Jasper Rymenants https://orcid.org/0000-0003-3838-310X

References
1. Westhoff TH, Vergoulidou M, Loddenkemper C, et al. Chronic norovirus infection in renal transplant recipients. Nephrol Dial Transplant 2009; 24: 1051–1053.
2. Green KY. Norovirus infection in immunocompromised hosts. Clin Microbiol Infect 2014; 20: 717–723.
3. Angarone MP, Sheahan A and Kamboj M. Norovirus in transplantation. Curr Infect Dis Rep 2016; 18: 17.
4. Rocha-Pereira J, Jochmans D, Dallmeier K, et al. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun 2012; 424: 777–780.
5. Rocha-Pereira J, Jochmans D, Dallmeier K, et al. Inhibition of norovirus replication by the nucleoside analogue 2'-C-methylcytidine. Biochem Biophys Res Commun 2012; 427: 796–800.
6. Rocha-Pereira J, Cunha R, Pinto DC, et al. (E)-2-styrylchromones as potential anti-norovirus agents. Bioorganic Med Chem 2010; 18: 4195–4201.
7. Baert L, Wobus CE, Van Coillie E, et al. Detection of murine norovirus 1 by using plaque assay, transfection assay, and real-time reverse transcription-PCR before and after heat exposure. Appl Environ Microbiol 2008; 74: 543–546.
8. Bray MA, Carpenter A, et al.; Imaging Platform BloMIT. Advanced assay development guidelines for Image-Based high content screening and analysis. In: Markossian S, Sittampalam GS, Grossman A, et al. (eds) Assay guidance manual. Bethesda, MD: Eli Lilly & Company and the National Center for Advancing Translational Sciences, 2004. https://www.ncbi.nlm.nih.gov/books/NBK126174/
9. Bassetto M, Van Dycke J, Neyts J, et al. Targeting the viral polymerase of diarrhea-causing viruses as a strategy to develop a single broad-spectrum antiviral therapy. Viruses 2019; 11: 173.
10. Rocha-Pereira J, Jochmans D, Debing Y, et al. The viral polymerase inhibitor 2'-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model. J Virol 2013; 87: 11798–11805.
11. Rocha-Pereira J, Jochmans D and Neyts J. Prophylactic treatment with the nucleoside analogue 2'-C-methylcytidine completely prevents transmission of norovirus. *J Antimicrob Chemother* 2015; 70: 190–197.

12. Rocha-Pereira J, Van Dycke J and Neyts J. Treatment with a nucleoside polymerase inhibitor reduces shedding of murine norovirus in stool to undetectable levels without emergence of drug-resistant variants. *Antimicrob Agents Chemother* 2015; 60: 1907–1911.

13. Van Dycke J, Ny A, Conceição-Neto N, et al. A robust human norovirus replication model in zebrafish larvae. *PLoS Pathog* 2019; 15: e1008009.

14. Kolawole AO, Rocha-Pereira J, Elftman MD, et al. Inhibition of human norovirus by a viral polymerase inhibitor in the B cell culture system and in the mouse model. *Antiviral Res* 2016; 132: 46–49.

15. Hosmillo M, Chaudhry Y, Nayak K, et al. Norovirus replication in human intestinal epithelial cells is restricted by the Interferon-induced JAK/STAT signaling pathway and RNA polymerase II-mediated transcriptional responses. *mBio* 2020; 11(2): e00215–20.

16. Van Dycke J, Rymenants J, Neyts J, et al. Assessment of the anti-norovirus activity in cell culture using the mouse norovirus: Early mechanistic studies. *Antivir Chem Chemother* 2021; 29: 1–6.